

and/or nitro. A specific example of a nitro substituted product is provided in Example 35 and claimed in Claim 25. By amendment, applicants have deleted the cyano substituent from Claim 1 in compliance with the rejection. This rejection is not applicable to Claims 2 and 3 because they specifically define the R₅ and R₆ groups without inclusion of either the cyano or nitro substituents.

The definition of the dotted line in the structural formula appearing in new Claim 37 limits that unsaturation to olefinic unsaturation in conformity with the definition of the reactant "cyclo-alkenone" given on page 3, line 2 of the third paragraph, Example 32, and the species of Claim 20. Although the single dotted line objected to would normally be construed to represent, when present, a double bond, the language employed in Claim 37 leaves no doubt that acetylenic unsaturation is not involved.

The title has been changed to read 2-phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives in an attempt to provide a more descriptive title.


References in addition to those presented in applicants' Information Disclosure Statement have been discovered in the European Patent Office. They are:

Mutak et al., Acta Pharm. Jugosl. 31, 17-26 (1981) which discloses compound 5 in scheme 1 on page 18. Compounds 5, 7 and 9, a and b, represent 2-alkyl-2-cyclohexenyl ethylamines and, c and d, 2-alkyl-2-cyclohexyl ethylamines which differ from the compounds now claimed in the absence of the -OR₄ group which is essential for anti-depressant activity. The reference compounds are analgesic agents, a property not shared by the claimed compounds.

Mutak et al., Acta Pharm. Jugosl. 31, 143-50 (1981) discloses cycloalkenyl butylamines no longer embraced by the claims of this application. These compounds are also disclosed to be analgesic agents.


French Patent 6408 (1968) discloses in the Figure sheet, the reduction of a nitrile (V) to obtain compound II, which by selection of substitutional variations could represent a generic statement of a non-N-alkylated analogue of the claimed compounds. However, the only compound disclosed which appears to be relevant and contains a phenyl group appears in Example 3 where the starting material is given as

2 different
1 ambiguous
as intermediate



a non-N-alkylated benzylamine derivative useful as an intermediate in the production of an analgesic azalactone. This reference presents the work of Maillard et al., Bull. Soc. Chim. France, as presented in the Information Disclosure Statement.

Rajsner et al., Coll. Czech. Chem. Com. 28 1031-1043 (1963) discloses on page 1040 the compound




as an intermediate.

Auslegeschrift 1,124,485 discloses some 1-phenyl-1-aminomethyl cycloalkanes as analgesics.

None of these references appear to be more relevant to the invention as now claimed than are the references presented in the Information Disclosure Statement.

Thus, it is submitted that this application is in condition for allowance and that action is requested.

Respectfully submitted,


Richard K. Jackson
Reg. No. 24,348

Dated: December 3, 1984

Telephone: (215) 341-2310